Health Care & Life Sciences » Biotechnology | Organovo Holdings Inc.

Organovo Holdings Inc. | Cash Flow

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
25,848.00
30,082.00
38,575.00
38,447.00
34,803.00
26,635
Depreciation, Depletion & Amortization
387.00
472.00
815.00
1,149.00
1,267.00
980
Other Funds
10,139.00
7,393.00
8,481.00
7,444.00
6,924.00
5,256
Funds from Operations
15,322.00
22,217.00
29,279.00
29,854.00
26,612.00
20,399
Changes in Working Capital
239.00
2,616.00
89.00
669.00
2,245.00
24
Net Operating Cash Flow
15,561.00
19,601.00
29,368.00
29,185.00
28,857.00
20,375
Capital Expenditures
277.00
1,517.00
2,149.00
1,354.00
296.00
Sale of Fixed Assets & Businesses
-
-
14.00
11.00
4.00
Purchase/Sale of Investments
-
-
-
48.00
-
Net Investing Cash Flow
268.00
1,517.00
2,135.00
1,391.00
292.00
Issuance/Reduction of Debt, Net
50.00
10.00
5.00
-
-
Net Financing Cash Flow
48,368.00
23,093.00
43,452.00
31,247.00
10,113.00
Net Change in Cash
32,539.00
1,975.00
11,949.00
660.00
19,025.00
Free Cash Flow
15,838.00
21,118.00
31,482.00
30,539.00
29,083.00
Other Sources
9.00
-
-
-
-
Change in Capital Stock
48,418.00
23,103.00
43,457.00
31,247.00
10,113.00
Exchange Rate Effect
-
-
-
11.00
11.00

About Organovo Holdings

View Profile
Address
6275 Nancy Ridge Drive
San Diego California 92121
United States
Employees -
Website http://www.organovo.com
Updated 07/08/2019
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions.